Dr. Hamilton on Extended Adjuvant Therapy for HER2+ Breast Cancer

Video

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the role of extended adjuvant therapy for patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the role of extended adjuvant therapy for patients with HER2-positive breast cancer.

The role of extended adjuvant therapy in HER2-positive breast cancer may not be quite as clear as in estrogen receptor—positive disease, but there is a benefit, explains Hamilton. For those women who have a higher risk and are motivated, it is a reasonable option.

It is important to be careful with neratinib (Nerlynx) due to the toxicity, as there is significant diarrhea associated with the drug. For women who are having trouble tolerating it despite antidiarrheals, or for women who do not have a high risk for recurrence, it may not be worth it in this setting. However, for women who are high risk and can tolerate it, it is a valuable option, states Hamilton.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD